Watch for Arbutus's next development plan for AB-101, including trial design and enrollment timeline. The Phase 1b data showing HBsAg decline in 2 patients at 30mg provides a proof-of-concept signal worth monitoring in future readouts.
Price Chart
Executive Summary
Arbutus Biopharma announced that the FDA has lifted the clinical hold on the IND for AB-101, its oral PD-L1 inhibitor for chronic HBV. The company may now resume U.S. clinical development, though it is still evaluating next steps. This removes a key regulatory overhang for the AB-101 program.
Key Facts
- FDA lifted clinical hold on IND for AB-101, an oral PD-L1 inhibitor for chronic HBV
- AB-101 completed Phase 1a/1b trial showing generally well-tolerated safety, high receptor occupancy in 7 cHBV patients, and HBsAg decline in 2 patients at 30mg dose
- Arbutus is evaluating next steps for continued development of AB-101
- AB-101 is a proprietary oral PD-L1 inhibitor designed to activate HBV-specific immune response
Financial Impact
No financial figures disclosed; clinical hold removal removes a regulatory barrier for the AB-101 program, which has no approved product or reported revenue
Risk Factors
- AB-101 is still early-stage; no guarantee of successful Phase 2/3 trials
- Arbutus has no approved products and relies on pipeline advancement and IP litigation for value
- Clinical hold removal does not guarantee rapid or successful development
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006753 |
| Exhibit: exh_991.htm | 0001171843-26-006753 |
| Document: 0001171843-26-006753-index-headers.html | 0001171843-26-006753 |
| Document: 0001171843-26-006753-index.html | 0001171843-26-006753 |
| Document: 0001171843-26-006753.txt | 0001171843-26-006753 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $4.21 | awaiting T+60 | — | $4.20 (−0.24%) |
Oct 22, 2026 4d ago | Press Release | $4.21 | awaiting T+60 | — | $4.20 (−0.24%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.18 | awaiting T+60 | — | $4.20 (+0.48%) |
Oct 5, 2026 21d ago | SC 13D/A | $4.48 | awaiting T+60 | — | $4.20 (−6.25%) |
Oct 1, 2026 25d ago | SC TO-I/A | $4.56 | awaiting T+60 | — | $4.20 (−7.89%) |
Oct 1, 2026 25d ago | Press Release | $4.56 | awaiting T+60 | — | $4.20 (−7.89%) |
Sep 30, 2026 26d ago | SC TO-I/A | $4.78 | awaiting T+60 | — | $4.20 (−12.13%) |
Sep 30, 2026 26d ago | Press Release | $4.78 | awaiting T+60 | — | $4.20 (−12.13%) |
Aug 21, 2026 9w ago | 8-K | $5.21 | awaiting T+60 | — | $4.20 (−19.39%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.71 | awaiting T+60 | — | $4.20 (−10.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers